KCM
ABBV icon

Kingdon Capital Management’s AbbVie ABBV Stock Holding History

Kingdon Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-150,000
Closed -$9.77M – 100
2017
Q1 		$9.77M Buy
+150,000
New +$9.43M 0.54% 53
2016
Q3 		– Sell
-200,000
Closed -$12.4M – 118
2016
Q2 		$12.4M Buy
+200,000
New +$12.2M 0.68% 44

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Kingdon Capital Management's ABBV Position: Q1 2022 in Review

Kingdon Capital Management sold out of AbbVie (ABBV) in Q1 2022, closing a stake of 99,200 shares — an estimated $13.4M sold.

Kingdon Capital Management first reported a position in ABBV in Q4 2021 and held it in 1 quarter. The position peaked at $13.4M in Q4 2021. 3,053 funds tracked by Wall St. Rank hold ABBV as of Q1 2022.

  • Kingdon Capital Management reported no remaining AbbVie position as of Q1 2022 after selling out during the quarter.
  • Kingdon Capital Management sold 99,200 AbbVie shares in Q1 2022, an estimated $13.4M.
  • Kingdon Capital Management first reported a position in AbbVie in Q4 2021 and held it in 1 quarter.
  • Kingdon Capital Management's AbbVie position peaked at $13.4M in Q4 2021.
  • 3,053 funds tracked by Wall St. Rank held AbbVie as of Q1 2022.

Based on Kingdon Capital Management's 13F filing for Q1 2022, filed 16 May 2022.